4D Molecular Therapeutics Inc (NASDAQ: FDMT) kicked off on Monday, down -10.97% from the previous trading day, before settling in for the closing price of $5.97. Over the past 52 weeks, FDMT has traded in a range of $4.43-$36.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 151.75%. While this was happening, its average annual earnings per share was recorded -12.47%. With a float of $38.01 million, this company’s outstanding shares have now reached $52.00 million.
The extent of productivity of a business whose workforce counts for 147 workers is very important to gauge. In terms of profitability, gross margin is -43747.06%, operating margin of -990447.06%, and the pretax margin is -844000.0%.
4D Molecular Therapeutics Inc (FDMT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 17.77%, while institutional ownership is 97.48%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.87 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.10% during the next five years compared to -46.35% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Take a look at 4D Molecular Therapeutics Inc’s (FDMT) current performance indicators. Last quarter, stock had a quick ratio of 17.33.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
The latest stats from [4D Molecular Therapeutics Inc, FDMT] show that its last 5-days average volume of 1.56 million was superior to 0.89 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 58.59%. Additionally, its Average True Range was 0.51.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 6.82%, which indicates a significant decrease from 35.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 96.49% in the past 14 days, which was higher than the 79.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.97, while its 200-day Moving Average is $14.13. Now, the first resistance to watch is $5.86. This is followed by the second major resistance level at $6.41. The third major resistance level sits at $6.71. If the price goes on to break the first support level at $5.02, it is likely to go to the next support level at $4.72. Assuming the price breaks the second support level, the third support level stands at $4.18.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
The company with the Market Capitalisation of 245.70 million has total of 46,228K Shares Outstanding. Its annual sales at the moment are 20,720 K in contrast with the sum of -100,840 K annual income. Company’s last quarter sales were recorded 10 K and last quarter income was -34,950 K.
